Periprocedural cilostazol treatment and restenosis after carotid artery stenting: The retrospective study of in-stent restenosis after carotid artery stenting (ReSISteR-CAS)

Hiroshi Yamagami, Nobuyuki Sakai, Yuji Matsumaru, Chiaki Sakai, Yutaka Kai, Kenji Sugiu, Toshiyuki Fujinaka, Yasushi Matsumoto, Shigeru Miyachi, Shinichi Yoshimura, Toshio Hyogo, Naoya Kuwayama, Akio Hyodo

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Restenosis after carotid artery stenting (CAS) is a critical issue. Cilostazol can reduce restenosis after interventions in coronary or femoropopliteal arteries. We investigated whether periprocedural cilostazol treatment was related to the incidence of in-stent restenosis (ISR) or target vessel revascularization (TVR) after CAS. The study group comprised 553 of 580 patients who underwent CAS between April 2003 and August 2006 and were followed for 30 months after the procedure. ISR was defined as stenosis of at least 50% detected on angiography or ultrasonography. TVR was defined as revascularization of the treated carotid artery. During CAS, 207 patients (37.4%) were treated with cilostazol. Over 30 months, ISR occurred in 23 patients (4.2%), TVR occurred in 16 patients (2.9%), and either ISR or TVR occurred in 25 patients (4.5%). The incidence of ISR or TVR was significantly lower in the cilostazol-treated group than in the untreated group (1.4% vs 6.4%; log-rank P =.006). In a multivariate analysis, cilostazol treatment (hazard ratio [HR], 0.28; 95% confidence interval [CI], 0.08-0.95; P =.041) and stent diameter (HR, 0.73/1-mm increase; 95% CI, 0.54-0.99; P =.044) were independent factors for the occurrence of ISR or TVR. The incidence of a composite of events, including thromboembolism, hemorrhage, death, and TVR, tended to be lower in the cilostazol-treated group than in the untreated group (15.0% vs 19.9%; log-rank P =.17). Periprocedural cilostazol treatment was associated with lower rates of ISR and retreatment after CAS. A prospective randomized controlled trial is needed to clarify the effect of cilostazol on ISR after CAS.

Original languageEnglish
Pages (from-to)193-199
Number of pages7
JournalJournal of Stroke and Cerebrovascular Diseases
Volume21
Issue number3
DOIs
Publication statusPublished - Apr 2012

Fingerprint

Carotid Arteries
Stents
Retrospective Studies
Therapeutics
Incidence
Confidence Intervals
cilostazol
Retreatment
Thromboembolism
Ultrasonography
Angiography
Pathologic Constriction
Multivariate Analysis
Randomized Controlled Trials
Arteries
Hemorrhage

Keywords

  • antiplatelet therapy
  • carotid artery stenosis
  • Endovascular therapy

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery
  • Rehabilitation
  • Cardiology and Cardiovascular Medicine

Cite this

Periprocedural cilostazol treatment and restenosis after carotid artery stenting : The retrospective study of in-stent restenosis after carotid artery stenting (ReSISteR-CAS). / Yamagami, Hiroshi; Sakai, Nobuyuki; Matsumaru, Yuji; Sakai, Chiaki; Kai, Yutaka; Sugiu, Kenji; Fujinaka, Toshiyuki; Matsumoto, Yasushi; Miyachi, Shigeru; Yoshimura, Shinichi; Hyogo, Toshio; Kuwayama, Naoya; Hyodo, Akio.

In: Journal of Stroke and Cerebrovascular Diseases, Vol. 21, No. 3, 04.2012, p. 193-199.

Research output: Contribution to journalArticle

Yamagami, Hiroshi ; Sakai, Nobuyuki ; Matsumaru, Yuji ; Sakai, Chiaki ; Kai, Yutaka ; Sugiu, Kenji ; Fujinaka, Toshiyuki ; Matsumoto, Yasushi ; Miyachi, Shigeru ; Yoshimura, Shinichi ; Hyogo, Toshio ; Kuwayama, Naoya ; Hyodo, Akio. / Periprocedural cilostazol treatment and restenosis after carotid artery stenting : The retrospective study of in-stent restenosis after carotid artery stenting (ReSISteR-CAS). In: Journal of Stroke and Cerebrovascular Diseases. 2012 ; Vol. 21, No. 3. pp. 193-199.
@article{51c5637fc96a45b585156f7db51cd326,
title = "Periprocedural cilostazol treatment and restenosis after carotid artery stenting: The retrospective study of in-stent restenosis after carotid artery stenting (ReSISteR-CAS)",
abstract = "Restenosis after carotid artery stenting (CAS) is a critical issue. Cilostazol can reduce restenosis after interventions in coronary or femoropopliteal arteries. We investigated whether periprocedural cilostazol treatment was related to the incidence of in-stent restenosis (ISR) or target vessel revascularization (TVR) after CAS. The study group comprised 553 of 580 patients who underwent CAS between April 2003 and August 2006 and were followed for 30 months after the procedure. ISR was defined as stenosis of at least 50{\%} detected on angiography or ultrasonography. TVR was defined as revascularization of the treated carotid artery. During CAS, 207 patients (37.4{\%}) were treated with cilostazol. Over 30 months, ISR occurred in 23 patients (4.2{\%}), TVR occurred in 16 patients (2.9{\%}), and either ISR or TVR occurred in 25 patients (4.5{\%}). The incidence of ISR or TVR was significantly lower in the cilostazol-treated group than in the untreated group (1.4{\%} vs 6.4{\%}; log-rank P =.006). In a multivariate analysis, cilostazol treatment (hazard ratio [HR], 0.28; 95{\%} confidence interval [CI], 0.08-0.95; P =.041) and stent diameter (HR, 0.73/1-mm increase; 95{\%} CI, 0.54-0.99; P =.044) were independent factors for the occurrence of ISR or TVR. The incidence of a composite of events, including thromboembolism, hemorrhage, death, and TVR, tended to be lower in the cilostazol-treated group than in the untreated group (15.0{\%} vs 19.9{\%}; log-rank P =.17). Periprocedural cilostazol treatment was associated with lower rates of ISR and retreatment after CAS. A prospective randomized controlled trial is needed to clarify the effect of cilostazol on ISR after CAS.",
keywords = "antiplatelet therapy, carotid artery stenosis, Endovascular therapy",
author = "Hiroshi Yamagami and Nobuyuki Sakai and Yuji Matsumaru and Chiaki Sakai and Yutaka Kai and Kenji Sugiu and Toshiyuki Fujinaka and Yasushi Matsumoto and Shigeru Miyachi and Shinichi Yoshimura and Toshio Hyogo and Naoya Kuwayama and Akio Hyodo",
year = "2012",
month = "4",
doi = "10.1016/j.jstrokecerebrovasdis.2010.06.007",
language = "English",
volume = "21",
pages = "193--199",
journal = "Journal of Stroke and Cerebrovascular Diseases",
issn = "1052-3057",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Periprocedural cilostazol treatment and restenosis after carotid artery stenting

T2 - The retrospective study of in-stent restenosis after carotid artery stenting (ReSISteR-CAS)

AU - Yamagami, Hiroshi

AU - Sakai, Nobuyuki

AU - Matsumaru, Yuji

AU - Sakai, Chiaki

AU - Kai, Yutaka

AU - Sugiu, Kenji

AU - Fujinaka, Toshiyuki

AU - Matsumoto, Yasushi

AU - Miyachi, Shigeru

AU - Yoshimura, Shinichi

AU - Hyogo, Toshio

AU - Kuwayama, Naoya

AU - Hyodo, Akio

PY - 2012/4

Y1 - 2012/4

N2 - Restenosis after carotid artery stenting (CAS) is a critical issue. Cilostazol can reduce restenosis after interventions in coronary or femoropopliteal arteries. We investigated whether periprocedural cilostazol treatment was related to the incidence of in-stent restenosis (ISR) or target vessel revascularization (TVR) after CAS. The study group comprised 553 of 580 patients who underwent CAS between April 2003 and August 2006 and were followed for 30 months after the procedure. ISR was defined as stenosis of at least 50% detected on angiography or ultrasonography. TVR was defined as revascularization of the treated carotid artery. During CAS, 207 patients (37.4%) were treated with cilostazol. Over 30 months, ISR occurred in 23 patients (4.2%), TVR occurred in 16 patients (2.9%), and either ISR or TVR occurred in 25 patients (4.5%). The incidence of ISR or TVR was significantly lower in the cilostazol-treated group than in the untreated group (1.4% vs 6.4%; log-rank P =.006). In a multivariate analysis, cilostazol treatment (hazard ratio [HR], 0.28; 95% confidence interval [CI], 0.08-0.95; P =.041) and stent diameter (HR, 0.73/1-mm increase; 95% CI, 0.54-0.99; P =.044) were independent factors for the occurrence of ISR or TVR. The incidence of a composite of events, including thromboembolism, hemorrhage, death, and TVR, tended to be lower in the cilostazol-treated group than in the untreated group (15.0% vs 19.9%; log-rank P =.17). Periprocedural cilostazol treatment was associated with lower rates of ISR and retreatment after CAS. A prospective randomized controlled trial is needed to clarify the effect of cilostazol on ISR after CAS.

AB - Restenosis after carotid artery stenting (CAS) is a critical issue. Cilostazol can reduce restenosis after interventions in coronary or femoropopliteal arteries. We investigated whether periprocedural cilostazol treatment was related to the incidence of in-stent restenosis (ISR) or target vessel revascularization (TVR) after CAS. The study group comprised 553 of 580 patients who underwent CAS between April 2003 and August 2006 and were followed for 30 months after the procedure. ISR was defined as stenosis of at least 50% detected on angiography or ultrasonography. TVR was defined as revascularization of the treated carotid artery. During CAS, 207 patients (37.4%) were treated with cilostazol. Over 30 months, ISR occurred in 23 patients (4.2%), TVR occurred in 16 patients (2.9%), and either ISR or TVR occurred in 25 patients (4.5%). The incidence of ISR or TVR was significantly lower in the cilostazol-treated group than in the untreated group (1.4% vs 6.4%; log-rank P =.006). In a multivariate analysis, cilostazol treatment (hazard ratio [HR], 0.28; 95% confidence interval [CI], 0.08-0.95; P =.041) and stent diameter (HR, 0.73/1-mm increase; 95% CI, 0.54-0.99; P =.044) were independent factors for the occurrence of ISR or TVR. The incidence of a composite of events, including thromboembolism, hemorrhage, death, and TVR, tended to be lower in the cilostazol-treated group than in the untreated group (15.0% vs 19.9%; log-rank P =.17). Periprocedural cilostazol treatment was associated with lower rates of ISR and retreatment after CAS. A prospective randomized controlled trial is needed to clarify the effect of cilostazol on ISR after CAS.

KW - antiplatelet therapy

KW - carotid artery stenosis

KW - Endovascular therapy

UR - http://www.scopus.com/inward/record.url?scp=84858789489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858789489&partnerID=8YFLogxK

U2 - 10.1016/j.jstrokecerebrovasdis.2010.06.007

DO - 10.1016/j.jstrokecerebrovasdis.2010.06.007

M3 - Article

C2 - 20851621

AN - SCOPUS:84858789489

VL - 21

SP - 193

EP - 199

JO - Journal of Stroke and Cerebrovascular Diseases

JF - Journal of Stroke and Cerebrovascular Diseases

SN - 1052-3057

IS - 3

ER -